| Name | Title | Contact Details |
|---|
Syan Biosciences is a Halethorpe, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Diagenics is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Edifice Health is a digital health spin-out company from a 10-year Stanford research in human immunology offering a novel metric of inflammatory health.
At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow`s breakthrough treatments. GlycoMimetics is a clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Since the company`s inception in 2003, we have developed a robust, diversified product pipeline. We are a public company traded on the NASDAQ under the symbol GLYC.
Acorda Therapeutics is a publicly traded (NASDAQ: ACOR) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. We started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. We have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. We achieve our goals by: • investing in research and development • collaborating closely with the patient, medical and scientific communities • retaining employees with compassion and commitment Acorda has been voted one of the best companies to work for in New York for the past five years in a row, as a result of our dynamic environment, strong corporate culture, significant emphasis on research and development, and a robust product pipeline. We are positioned to be an industry leader, poised for exceptional growth.